ID   RIOK2_HUMAN             Reviewed;         552 AA.
AC   Q9BVS4; D6RDI3; Q9NUT0;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   12-OCT-2022, entry version 178.
DE   RecName: Full=Serine/threonine-protein kinase RIO2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:19564402, ECO:0000269|PubMed:21880710};
DE   AltName: Full=RIO kinase 2;
GN   Name=RIOK2 {ECO:0000312|HGNC:HGNC:18999};
GN   Synonyms=RIO2 {ECO:0000303|PubMed:21880710};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-349.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hepatoma;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT TYR-144.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=16037817; DOI=10.1038/sj.emboj.7600752;
RA   Rouquette J., Choesmel V., Gleizes P.E.;
RT   "Nuclear export and cytoplasmic processing of precursors to the 40S
RT   ribosomal subunits in mammalian cells.";
RL   EMBO J. 24:2862-2872(2005).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-390, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332; SER-335; SER-337;
RP   SER-390; SER-417 AND SER-442, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350; SER-380; SER-382;
RP   SER-385 AND SER-442, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, NUCLEAR EXPORT SIGNAL,
RP   PHOSPHORYLATION, AND MUTAGENESIS OF LYS-123; ASP-246; LEU-400 AND ILE-403.
RX   PubMed=19564402; DOI=10.1083/jcb.200904048;
RA   Zemp I., Wild T., O'Donohue M.F., Wandrey F., Widmann B., Gleizes P.E.,
RA   Kutay U.;
RT   "Distinct cytoplasmic maturation steps of 40S ribosomal subunit precursors
RT   require hRio2.";
RL   J. Cell Biol. 185:1167-1180(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332; SER-335; SER-337;
RP   SER-362; SER-385; SER-390; SER-442 AND TYR-445, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332; SER-335; SER-337;
RP   SER-380; SER-382; SER-385 AND SER-390, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332; SER-335; SER-337 AND
RP   SER-412, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   SUBUNIT.
RX   PubMed=21081503; DOI=10.1074/jbc.m110.148486;
RA   Guderian G., Peter C., Wiesner J., Sickmann A., Schulze-Osthoff K.,
RA   Fischer U., Grimmler M.;
RT   "RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5),
RT   competes with pICln for binding and modulates PRMT5 complex composition and
RT   substrate specificity.";
RL   J. Biol. Chem. 286:1976-1986(2011).
RN   [16]
RP   PHOSPHORYLATION AT SER-335; SER-380 AND SER-548 BY PLK1, FUNCTION,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF SER-335; SER-380 AND SER-548, AND
RP   INTERACTION WITH PLK1.
RX   PubMed=21880710; DOI=10.1074/jbc.m111.250175;
RA   Liu T., Deng M., Li J., Tong X., Wei Q., Ye X.;
RT   "Phosphorylation of right open reading frame 2 (Rio2) protein kinase by
RT   polo-like kinase 1 regulates mitotic progression.";
RL   J. Biol. Chem. 286:36352-36360(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-337, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332; SER-335; SER-337;
RP   SER-350; SER-380; SER-382; SER-390; SER-412 AND SER-442, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-96; ARG-144; HIS-155; ILE-175; THR-216;
RP   VAL-244; ARG-349; SER-397; ASP-409 AND HIS-507.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in the final steps
CC       of cytoplasmic maturation of the 40S ribosomal subunit. Involved in
CC       export of the 40S pre-ribosome particles (pre-40S) from the nucleus to
CC       the cytoplasm. Its kinase activity is required for the release of NOB1,
CC       PNO1 and LTV1 from the late pre-40S and the processing of 18S-E pre-
CC       rRNA to the mature 18S rRNA (PubMed:19564402). Regulates the timing of
CC       the metaphase-anaphase transition during mitotic progression, and its
CC       phosphorylation, most likely by PLK1, regulates this function
CC       (PubMed:21880710). {ECO:0000269|PubMed:16037817,
CC       ECO:0000269|PubMed:19564402, ECO:0000269|PubMed:21880710}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:19564402, ECO:0000269|PubMed:21880710};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:19564402,
CC         ECO:0000269|PubMed:21880710};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC   -!- SUBUNIT: Associated with late 40S pre-ribosomal particles
CC       (PubMed:16037817, PubMed:21081503). Interacts with PLK1 (via its N-
CC       terminus) (PubMed:21880710). {ECO:0000269|PubMed:16037817,
CC       ECO:0000269|PubMed:21880710}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16037817,
CC       ECO:0000269|PubMed:19564402}. Note=Exported out of the nucleus via its
CC       NES in a XPO1-dependent manner. {ECO:0000269|PubMed:19564402}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BVS4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BVS4-2; Sequence=VSP_046388;
CC   -!- PTM: Autophosphorylated (in vitro) (PubMed:19564402, PubMed:21880710).
CC       Phosphorylation at Ser-335, Ser-380, Ser-548 by PLK1 affects the timing
CC       of the metaphase-anaphase transition (PubMed:21880710).
CC       {ECO:0000269|PubMed:19564402, ECO:0000269|PubMed:21880710}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. RIO-type Ser/Thr
CC       kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK002021; BAA92040.1; -; mRNA.
DR   EMBL; AK225348; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC008865; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC008883; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000953; AAH00953.1; -; mRNA.
DR   CCDS; CCDS4089.1; -. [Q9BVS4-1]
DR   CCDS; CCDS54884.1; -. [Q9BVS4-2]
DR   RefSeq; NP_001153221.1; NM_001159749.1. [Q9BVS4-2]
DR   RefSeq; NP_060813.2; NM_018343.2. [Q9BVS4-1]
DR   PDB; 5DHF; X-ray; 2.29 A; D=389-403.
DR   PDB; 6FDM; X-ray; 2.10 A; A/B/C/D=1-313.
DR   PDB; 6FDN; X-ray; 2.90 A; A/B=1-320.
DR   PDB; 6FDO; X-ray; 2.60 A; A/B=1-353.
DR   PDB; 6G18; EM; 3.60 A; v=1-552.
DR   PDB; 6G51; EM; 4.10 A; v=1-552.
DR   PDB; 6HK6; X-ray; 2.35 A; A/B/C/D/E/F/G/H/I/J=1-329.
DR   PDBsum; 5DHF; -.
DR   PDBsum; 6FDM; -.
DR   PDBsum; 6FDN; -.
DR   PDBsum; 6FDO; -.
DR   PDBsum; 6G18; -.
DR   PDBsum; 6G51; -.
DR   PDBsum; 6HK6; -.
DR   AlphaFoldDB; Q9BVS4; -.
DR   SMR; Q9BVS4; -.
DR   BioGRID; 120896; 95.
DR   IntAct; Q9BVS4; 41.
DR   STRING; 9606.ENSP00000283109; -.
DR   BindingDB; Q9BVS4; -.
DR   ChEMBL; CHEMBL6000; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9BVS4; -.
DR   GlyGen; Q9BVS4; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9BVS4; -.
DR   PhosphoSitePlus; Q9BVS4; -.
DR   BioMuta; RIOK2; -.
DR   DMDM; 143811448; -.
DR   EPD; Q9BVS4; -.
DR   jPOST; Q9BVS4; -.
DR   MassIVE; Q9BVS4; -.
DR   MaxQB; Q9BVS4; -.
DR   PaxDb; Q9BVS4; -.
DR   PeptideAtlas; Q9BVS4; -.
DR   PRIDE; Q9BVS4; -.
DR   ProteomicsDB; 14107; -.
DR   ProteomicsDB; 79230; -. [Q9BVS4-1]
DR   Antibodypedia; 13276; 343 antibodies from 26 providers.
DR   DNASU; 55781; -.
DR   Ensembl; ENST00000283109.8; ENSP00000283109.3; ENSG00000058729.11. [Q9BVS4-1]
DR   Ensembl; ENST00000508447.1; ENSP00000420932.1; ENSG00000058729.11. [Q9BVS4-2]
DR   GeneID; 55781; -.
DR   KEGG; hsa:55781; -.
DR   MANE-Select; ENST00000283109.8; ENSP00000283109.3; NM_018343.3; NP_060813.2.
DR   UCSC; uc003kmz.4; human. [Q9BVS4-1]
DR   CTD; 55781; -.
DR   DisGeNET; 55781; -.
DR   GeneCards; RIOK2; -.
DR   HGNC; HGNC:18999; RIOK2.
DR   HPA; ENSG00000058729; Low tissue specificity.
DR   MIM; 617754; gene.
DR   neXtProt; NX_Q9BVS4; -.
DR   OpenTargets; ENSG00000058729; -.
DR   PharmGKB; PA134885533; -.
DR   VEuPathDB; HostDB:ENSG00000058729; -.
DR   eggNOG; KOG2268; Eukaryota.
DR   GeneTree; ENSGT00390000003255; -.
DR   HOGENOM; CLU_018693_0_3_1; -.
DR   InParanoid; Q9BVS4; -.
DR   OMA; FEMTEFS; -.
DR   OrthoDB; 1010730at2759; -.
DR   PhylomeDB; Q9BVS4; -.
DR   TreeFam; TF321400; -.
DR   PathwayCommons; Q9BVS4; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; Q9BVS4; -.
DR   SIGNOR; Q9BVS4; -.
DR   BioGRID-ORCS; 55781; 775 hits in 1123 CRISPR screens.
DR   ChiTaRS; RIOK2; human.
DR   GenomeRNAi; 55781; -.
DR   Pharos; Q9BVS4; Tbio.
DR   PRO; PR:Q9BVS4; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9BVS4; protein.
DR   Bgee; ENSG00000058729; Expressed in oocyte and 179 other tissues.
DR   ExpressionAtlas; Q9BVS4; baseline and differential.
DR   Genevisible; Q9BVS4; HS.
DR   GO; GO:0005737; C:cytoplasm; IMP:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0030688; C:preribosome, small subunit precursor; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0030490; P:maturation of SSU-rRNA; IMP:UniProtKB.
DR   GO; GO:2000208; P:positive regulation of ribosomal small subunit export from nucleus; IMP:UniProtKB.
DR   GO; GO:2000234; P:positive regulation of rRNA processing; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; IMP:UniProtKB.
DR   GO; GO:0042274; P:ribosomal small subunit biogenesis; IMP:UniProtKB.
DR   CDD; cd05144; RIO2_C; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR030484; Rio2.
DR   InterPro; IPR015285; RIO2_wHTH_N.
DR   InterPro; IPR000687; RIO_kinase.
DR   InterPro; IPR018935; RIO_kinase_CS.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF09202; Rio2_N; 1.
DR   SMART; SM00090; RIO; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01245; RIO1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cytoplasm;
KW   Kinase; Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Ribosome biogenesis; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..552
FT                   /note="Serine/threonine-protein kinase RIO2"
FT                   /id="PRO_0000213527"
FT   DOMAIN          97..272
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000305"
FT   MOTIF           399..408
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000269|PubMed:19564402"
FT   ACT_SITE        228
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         123
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         332
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         335
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21880710,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         337
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         362
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21880710,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332"
FT   MOD_RES         390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         412
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         417
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         445
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         548
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   VAR_SEQ         467..552
FT                   /note="DEENVGAMNQYRTRTLSITSSGSAVSCSTIPPELVKQKVKRQLTKQQKSAVR
FT                   RRLQKGEANIFTKQRRENMQNIKSSLEAASFWGE -> YRLLSIAF (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_046388"
FT   VARIANT         96
FT                   /note="S -> C (in dbSNP:rs2544773)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042347"
FT   VARIANT         144
FT                   /note="H -> R (in dbSNP:rs35165987)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042348"
FT   VARIANT         144
FT                   /note="H -> Y (in dbSNP:rs17849382)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_031597"
FT   VARIANT         155
FT                   /note="R -> H (in dbSNP:rs34916955)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042349"
FT   VARIANT         175
FT                   /note="V -> I (in dbSNP:rs35713904)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042350"
FT   VARIANT         216
FT                   /note="I -> T (in a renal clear cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs147608663)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042351"
FT   VARIANT         244
FT                   /note="M -> V (in dbSNP:rs33996030)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042352"
FT   VARIANT         349
FT                   /note="G -> R (in dbSNP:rs160632)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_031598"
FT   VARIANT         397
FT                   /note="N -> S (in dbSNP:rs12188395)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_031599"
FT   VARIANT         409
FT                   /note="E -> D (in dbSNP:rs35829000)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042353"
FT   VARIANT         507
FT                   /note="R -> H (in dbSNP:rs34555783)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042354"
FT   MUTAGEN         123
FT                   /note="K->A: Abolishes autophosphorylation; impairs release
FT                   of pre-40S trans-acting factors and rRNA processing; when
FT                   associated with A-246."
FT                   /evidence="ECO:0000269|PubMed:19564402"
FT   MUTAGEN         246
FT                   /note="D->A: Abolishes autophosphorylation; impairs release
FT                   of pre-40S trans-acting factors and rRNA processing; when
FT                   associated with A-123."
FT                   /evidence="ECO:0000269|PubMed:19564402"
FT   MUTAGEN         335
FT                   /note="S->A: Does not affect autophosphorylation activity;
FT                   when associated with A-380 and A-548. Does not affect the
FT                   timing of metaphase-anaphase transition; when associated
FT                   with A-380 and A-548."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   MUTAGEN         335
FT                   /note="S->D: Increases time spent in metaphase; when
FT                   associated with D-380 and D-548."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   MUTAGEN         380
FT                   /note="S->A: Does not affect autophosphorylation activity;
FT                   when associated with A-335 and A-548. Does not affect the
FT                   timing of metaphase-anaphase transition; when associated
FT                   with A-335 and A-548."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   MUTAGEN         380
FT                   /note="S->D: Increases time spent in metaphase; when
FT                   associated with D-335 and D-548."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   MUTAGEN         400
FT                   /note="L->A: Nuclear relocalization; when associated with
FT                   A-403."
FT                   /evidence="ECO:0000269|PubMed:19564402"
FT   MUTAGEN         403
FT                   /note="I->A: Nuclear relocalization; when associated with
FT                   A-400."
FT                   /evidence="ECO:0000269|PubMed:19564402"
FT   MUTAGEN         548
FT                   /note="S->A: Does not affect autophosphorylation activity;
FT                   when associated with A-335 and A-380. Does not affect the
FT                   timing of metaphase-anaphase transition; when associated
FT                   with A-335 and A-380."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   MUTAGEN         548
FT                   /note="S->D: Increases time spent in metaphase; when
FT                   associated with D-335 and D-380."
FT                   /evidence="ECO:0000269|PubMed:21880710"
FT   HELIX           7..13
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           15..26
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   TURN            27..29
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          31..33
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           35..42
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           49..58
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          61..66
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          71..75
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           77..90
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          95..104
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          107..113
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          119..125
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          130..132
FT                   /evidence="ECO:0007829|PDB:6HK6"
FT   HELIX           147..170
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          178..182
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          185..189
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          192..195
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           196..198
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           205..221
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          233..237
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           258..277
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           287..289
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           298..311
FT                   /evidence="ECO:0007829|PDB:6FDM"
FT   HELIX           394..400
FT                   /evidence="ECO:0007829|PDB:5DHF"
SQ   SEQUENCE   552 AA;  63283 MW;  6EB260E72DDB78D7 CRC64;
     MGKVNVAKLR YMSRDDFRVL TAVEMGMKNH EIVPGSLIAS IASLKHGGCN KVLRELVKHK
     LIAWERTKTV QGYRLTNAGY DYLALKTLSS RQVVESVGNQ MGVGKESDIY IVANEEGQQF
     ALKLHRLGRT SFRNLKNKRD YHKHRHNVSW LYLSRLSAMK EFAYMKALYE RKFPVPKPID
     YNRHAVVMEL INGYPLCQIH HVEDPASVYD EAMELIVKLA NHGLIHGDFN EFNLILDESD
     HITMIDFPQM VSTSHPNAEW YFDRDVKCIK DFFMKRFSYE SELFPTFKDI RREDTLDVEV
     SASGYTKEMQ ADDELLHPLG PDDKNIETKE GSEFSFSDGE VAEKAEVYGS ENESERNCLE
     ESEGCYCRSS GDPEQIKEDS LSEESADARS FEMTEFNQAL EEIKGQVVEN NSVTEFSEEK
     NRTENYNRQD GQRVQGGVPA GSDEYEDECP HLIALSSLNR EFRPFRDEEN VGAMNQYRTR
     TLSITSSGSA VSCSTIPPEL VKQKVKRQLT KQQKSAVRRR LQKGEANIFT KQRRENMQNI
     KSSLEAASFW GE
//
